108149-61-7

Basic information

• Product Name: 3-(tert-butyl) 4-methyl (4S,5R)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate
• CAS NO: 108149-61-7
• Molecular Weight: 273.329
• Mol File: 108149-61-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 3-(tert-butyl) 4-methyl (4S,5R)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(tert-butyl) 4-methyl (4S,5R)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate(108149-61-7)
• EPA Substance Registry System: 3-(tert-butyl) 4-methyl (4S,5R)-2,2,5-trimethyloxazolidine-3,4-dicarboxylate(108149-61-7)

Safety Data

• Hazardous Substances Data: 108149-61-7(Hazardous Substances Data)

Upstream product

• 60538-19-4 N-(tert-butoxycarbonyl)-l-threonine methyl ester 
• 77-76-9 2,2-dimethoxy-propane 
• 116-11-0 2-Methoxypropene 
• 2592-18-9 N-(t-Butyloxycarbonyl)-L-threonine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 72-19-5 L-threonine 

Downstream Products

• 108149-62-8 (4S,5R)-3-(tert-Butoxycarbonyl)-4-formyl-2,2,5-trimethyloxazolidine 

Relevant articles and documents

A new access to enantiomerically pure deoxy aminohexoses: Methyl 4-amino-4,6-dideoxy gulopyranoside and epi-tolyposamine

New efficient synthetic routes have been developed starting from the fully protected L-threonine derivative 1 for some deoxy-4-aminohexoses: methyl 4-amino-4,6-dideoxy gulopyranoside 2 and epi-tolyposamine 3. The title compounds were synthesized using an improved Horner-Emmons reaction of the threonine derived aldehyde 7. A new method for selective removal of the aminal protection is also reported.

CYCLIZED SULFAMOYLARYLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I-A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY AND METHOD FOR THEIR PREPARATION

The present invention provides analogs of FR901464, as well as a methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.